Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 13c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.93, $0.13 better than the analyst estimate of $0.80. Revenue for the quarter came in at $48.1 million versus the consensus estimate of $45.86 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M